Intravesical therapy - BCG and beyond

Research output: Contribution to journalArticle

Abstract

Non-muscle invasive bladder cancer is marked by frequent recurrences and a risk for progression to life threatening disease. Intravesical Bacillus Calmette-Gúerin (BCG), one of the earliest effective immunotherapies for cancer, remains the current standard for treating high-risk non-muscle invasive bladder cancer. Optimal treatment with BCG includes periodic 3 weekly maintenance instillations, often with dose reduction to minimize toxicity. However, despite its efficacy, treatment failure is common. Efforts to provide alternate and potentially more effective therapy for this disease include increased understanding of bladder cancer through molecular profiling, multi-agent intravesical chemotherapy, and novel forms of immunotherapy.

Details

Authors
  • H. Barton Grossman
  • Donald Lamm
  • Gottfrid Sjodahl
  • Michael O'donnell
  • Noah Hahn
  • Ashish Kamat
Organisations
External organisations
  • University of Texas
  • University of Arizona
  • Skåne University Hospital
  • Johns Hopkins University
  • University of Iowa
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
  • Urology and Nephrology

Keywords

  • Bcg, Bladder cancer, Immunotherapy, Intravesical chemotherapy, Molecular profiling
Original languageEnglish
Pages (from-to)73-80
Number of pages8
JournalBladder Cancer
Volume5
Issue number1
Publication statusPublished - 2019
Publication categoryResearch
Peer-reviewedYes